Form 4: Apellis CMO Caroline Baumal Gifts 900 Shares

Chief Medical Officer Caroline Baumal donated 900 shares of Apellis Pharmaceuticals to charity while maintaining a substantial ownership stake.

Summary

• Caroline Baumal, Chief Medical Officer, disposed of 900 shares of common stock on April 29, 2026.
• The transaction was executed as a charitable contribution with a reported price of $0.00.
• Following this transaction, the reporting person beneficially owns 86,525 shares directly.
• The total ownership figure includes 898 shares acquired through an Employee Stock Purchase Plan (ESPP) on April 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; the disposal was for philanthropic purposes and the executive retains a high level of skin in the game.

Positives

• The executive maintains a significant direct ownership stake of 86,525 shares.
• The disposal was a charitable gift rather than an open-market sale, which typically indicates the transaction was not motivated by a negative outlook on the stock price.
• Continued participation in the Employee Stock Purchase Plan shows ongoing investment by the executive.

Negatives

• The reporting person's total direct shareholding decreased by a net amount of 2 shares when accounting for the gift and the ESPP purchase.

Risks

• Insider disposals, even for charitable purposes, reduce the total equity alignment between management and shareholders.

Future Outlook

No specific forward-looking guidance or strategic updates were provided in this ownership disclosure.

Industry Context

StockSavvy.ai notes that charitable donations by C-suite executives are common in the pharmaceutical industry and are generally viewed as neutral events by institutional investors compared to scheduled or unscheduled market sales.

Comparison to Industry Standards

• The transaction size is negligible compared to the company's total market capitalization.
• Executive ownership levels remain consistent with peer-group standards for mid-to-large cap biotechnology firms.

Related Party Transactions

• The reporting person gifted 900 shares of common stock for no consideration.

Stakeholder Impact

• Minimal impact on shareholders as the transaction does not involve a market sale and represents a very small fraction of the total shares outstanding.

Next Steps

• Monitor for further insider transactions that might indicate a trend in management sentiment.

Key Dates

Recommendation

This filing represents a routine administrative update regarding insider ownership and does not provide new material information regarding the company's operations or financial performance that would alter a valuation.

Keywords

Apellis Pharmaceuticals, APLS, Caroline Baumal, Insider Trading, Form 4, Charitable Gift, Biotechnology, Chief Medical Officer